Tirzepatide (Mounjaro) has rapidly become one of the most discussed medications in diabetes and obesity medicine. Its dual GIP/GLP-1 receptor agonist mechanism produces unprecedented reductions in blood sugar and body weight. But what does the evidence say about its cardiovascular effects — and how does it compare to semaglutide? How Tirzepatide Works Unlike semaglutide, which…
GLP-1 Medications and Heart Protection: What the Evidence Shows: cardiovascular outcome trial evidence, who benefits most, and how this drug class fits into.
New Research Confirms GLP-1 Medications Protect the Heart, Not Just Blood Sugar: cardiovascular outcome trial evidence, who benefits most, and how this drug.
English English 
Arabic
Spanish
Urdu